Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 21

1.

Tetrameric Acetyl-CoA Acetyltransferase 1 Is Important for Tumor Growth.

Fan J, Lin R, Xia S, Chen D, Elf SE, Liu S, Pan Y, Xu H, Qian Z, Wang M, Shan C, Zhou L, Lei QY, Li Y, Mao H, Lee BH, Sudderth J, DeBerardinis RJ, Zhang G, Owonikoko T, Gaddh M, Arellano ML, Khoury HJ, Khuri FR, Kang S, Doetsch PW, Lonial S, Boggon TJ, Curran WJ, Chen J.

Mol Cell. 2016 Dec 1;64(5):859-874. doi: 10.1016/j.molcel.2016.10.014.

PMID:
27867011
2.

Allosteric Modulation of Muscarinic Acetylcholine Receptors.

Jakubík J, El-Fakahany EE.

Pharmaceuticals (Basel). 2010 Aug 30;3(9):2838-2860. Review.

3.

Evaluation of arecoline hydrobromide toxicity after a 14-day repeated oral administration in Wistar rats.

Wei X, Zhang J, Niu J, Zhou X, Li J, Li B.

PLoS One. 2015 Apr 16;10(4):e0120165. doi: 10.1371/journal.pone.0120165.

4.

Long-term activation upon brief exposure to xanomleline is unique to M1 and M4 subtypes of muscarinic acetylcholine receptors.

Šantrůčková E, Doležal V, El-Fakahany EE, Jakubík J.

PLoS One. 2014 Feb 18;9(2):e88910. doi: 10.1371/journal.pone.0088910.

5.

Role of aqueous extract of Azadirachta indica leaves in an experimental model of Alzheimer's disease in rats.

Raghavendra M, Maiti R, Kumar S, Acharya S.

Int J Appl Basic Med Res. 2013 Jan;3(1):37-47. doi: 10.4103/2229-516X.112239.

6.

Functional and neurobiological similarities of aging in monkeys and humans.

Voytko ML.

Age (Omaha). 1997 Jan;20(1):29-44. doi: 10.1007/s11357-997-0003-3.

7.

Therapeutic approaches to age-associated neurocognitive disorders.

O'Hara R, Derouesné C, Fountoulakis KN, Yesavage JA.

Dialogues Clin Neurosci. 2001 Sep;3(3):191-213.

8.
9.

Synthesis of Novel 3-Aryl-N-Methyl-1,2,5,6-Tetrahydropyridine Derivatives by Suzuki coupling: As Acetyl Cholinesterase Inhibitors.

Prasad SB, Kumar YC, Kumar CS, Sadashiva CT, Vinaya K, Rangappa KS.

Open Med Chem J. 2007 Sep 5;1:4-10. doi: 10.2174/1874104500701010004.

10.

Hormesis and medicine.

Calabrese EJ.

Br J Clin Pharmacol. 2008 Nov;66(5):594-617. doi: 10.1111/j.1365-2125.2008.03243.x. Review.

11.

Correlates of response to acetylcholinesterase inhibitor therapy in Alzheimer's disease.

Lanctôt KL, Herrmann N, LouLou MM.

J Psychiatry Neurosci. 2003 Jan;28(1):13-26. Review.

12.

Neurotransmitter replacement therapy in Alzheimer's disease.

Mohr E, Mendis T, Rusk IN, Grimes JD.

J Psychiatry Neurosci. 1994 Jan;19(1):17-23. Review.

13.

Pharmacokinetics of physostigmine in man following a single application of a transdermal system.

Walter K, Müller M, Barkworth MF, Nieciecki AV, Stanislaus F.

Br J Clin Pharmacol. 1995 Jan;39(1):59-63.

14.

The noradrenergic system in Alzheimer and multi-infarct dementias.

Mann DM, Yates PO, Hawkes J.

J Neurol Neurosurg Psychiatry. 1982 Feb;45(2):113-9.

15.

Cholinergic system and constructional praxis: a further study of physostigmine in Alzheimer's disease.

Muramoto O, Sugishita M, Ando K.

J Neurol Neurosurg Psychiatry. 1984 May;47(5):485-91.

16.

Alzheimer's disease: recent advances and future prospects.

Deakin JF.

Br Med J (Clin Res Ed). 1983 Nov 5;287(6402):1323-4. No abstract available.

17.

A double-blind, placebo controlled trial of high-dose lecithin in Alzheimer's disease.

Little A, Levy R, Chuaqui-Kidd P, Hand D.

J Neurol Neurosurg Psychiatry. 1985 Aug;48(8):736-42.

18.

Critical review of clinical trials in senile dementia--II.

Orgogozo JM, Spiegel R.

Postgrad Med J. 1987 May;63(739):337-43. Review. No abstract available.

19.

The cholinergic pharmacology of tetrahydroaminoacridine in vivo and in vitro.

Hunter AJ, Murray TK, Jones JA, Cross AJ, Green AR.

Br J Pharmacol. 1989 Sep;98(1):79-86.

Items per page

Supplemental Content

Support Center